Andrew D. Leavitt, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Andrew D. Leavitt, MD

Professor, Departments of Laboratory Medicine and Medicine (Div. of Hematology/Oncology), UCSF

leavitta@labmed2.ucsf.edu

Phone: (415) 514-3432, 476-4217 (voice)
Box 0100, UCSF
San Francisco, CA 94143-0100

View on UCSF Profiles


Education

University of Michigan, Ann Arbor, B.S., 1979, Zoology
Harvard Medical School, M.D., 1984, Medicine

Professional Experience

  • 1982-1984
    Medical School Research Fellowship, Harvard Medical School, Department of Pediatric Hematology & Oncology (Laboratory of Dr. Robert Garcea; Project: Expression cloning, purification, and characterization of Polyoma major capsid protein, VP1)
  • 1984-1987
    Intern and Resident, Department of Internal Medicine, University of Michigan Hospitals
  • 1987-1988
    Chief Resident, Department of Internal Medicine, University of Michigan Hospitals
  • 1988-1991
    Hematology/Oncology Fellow, University of California, San Francisco
  • 1991-1992
    Molecular Medicine Fellow, University of California, San Francisco
  • 1989-1992
    Post-doctoral Research Fellow, University of California, San Francisco, Department of Microbiology & Immunology (Laboratory of Dr. Harold Varmus; Project: Biochemical characterization of retroviral integration)
  • 1992-2001
    Assistant Professor-in-residence, Department of Laboratory Medicine & Department of Medicine, UCSF
  • 1992-present
    Assistant Director, Blood Bank, Moffit-Long Hospitals, UCSF
  • 1994-present
    Medical Director, Adult Hematopoietic Progenitor Cell & Cellular Therapy Laboratory, Moffitt-Long Hospitals, UCSF
  • 2001-2007
    Associate Professor in Residence, Departments of Laboratory Medicine and Medicine (Div. of Hematology/Oncology), UCSF
  • 2007-present
    Professor in Residence, Departments of Laboratory Medicine and Medicine (Div. of Hematology/Oncology), UCSF

Honors & Awards

  • 1978-79
    James B. Angell Scholar, University of Michigan
  • 1979
    Phi Beta Kappa, University of Michigan
  • 1982-83
    Karin Grunebaum Cancer Research Foundation Fellowship, Harvard Medical School
  • 1984
    Cum Laude, Harvard Medical School
  • 1985
    Outstanding House Officer Award, Department of Internal Medicine, University of Michigan
  • 1991-92
    Burroughs Wellcome Research Fellowship
  • 1998
    Nomination for Small Group Teaching Award; UCSF Class of 2000
  • 2000
    Nomination for Small Group Teaching and Outstanding Lecture Award; UCSF Class of 2002
  • 2002
    Outstanding Lecture Award; UCSF Class of 2005
  • 2003
    Nominated for Kaiser Award for Excellence in Teaching
  • 2006
    Excellence in Teaching Award from the Haile T. Debas Academy of Medical Educator-UCSF

Selected Publications

  1. Roubinian NH, Leavitt AD. Shedding a little light on posttransfusion purpura. Transfusion. 2015 Feb; 55(2):232-4.
    View on PubMed
  2. Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, Cosgrove K, Vojnik R, Calfee CS, Lee JW, Rogers AJ, Levitt J, Wiener-Kronish J, Bajwa EK, Leavitt A, McKenna D, Thompson BT, Matthay MA. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015 Jan; 3(1):24-32.
    View on PubMed
  3. Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM, Wolf JL, Caballero L, Emi N, Martin TG. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. Bone Marrow Transplant. 2015 Jan; 50(1):40-4.
    View on PubMed
  4. Liu KD, Wilson JG, Zhuo H, Caballero L, McMillan ML, Fang X, Cosgrove K, Calfee CS, Lee JW, Kangelaris KN, Gotts JE, Rogers AJ, Levitt JE, Wiener-Kronish JP, Delucchi KL, Leavitt AD, McKenna DH, Thompson BT, Matthay MA. Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. Ann Intensive Care. 2014; 4:22.
    View on PubMed
  5. Kamata T, Dankort D, Kang J, Giblett S, Pritchard CA, McMahon M, Leavitt AD. Hematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720. Mol Cancer Res. 2013 Dec; 11(12):1530-41.
    View on PubMed
  6. Jacquot C, Moayeri M, Kim B, Shugarts S, Lynch KL, Leavitt AD. Prolonged ceftriaxone-induced immune thrombocytopenia due to impaired drug clearance: a case report. Transfusion. 2013 Nov; 53(11):2715-21.
    View on PubMed
  7. Choi YS, Patena W, Leavitt AD, McManus MT. Widespread RNA 3'-end oligouridylation in mammals. RNA. 2012 Mar; 18(3):394-401.
    View on PubMed
  8. Leavitt AD, Hamlett I. Homologous recombination in human embryonic stem cells: a tool for advancing cell therapy and understanding and treating human disease. Clin Transl Sci. 2011 Aug; 4(4):298-305.
    View on PubMed
  9. Bu W, Chen J, Morrison GD, Huang S, Creighton CJ, Huang J, Chamness GC, Hilsenbeck SG, Roop DR, Leavitt AD, Li Y. Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer. Oncogene. 2011 Oct 27; 30(43):4399-409.
    View on PubMed
  10. Leavitt AD. A vote for scientists as politicians. Science. 2011 Feb 25; 331(6020):1010.
    View on PubMed
  11. Leavitt AD. Are there more tricks in the bag for treating thrombocytopenia? J Clin Invest. 2010 Nov; 120(11):3807-10.
    View on PubMed
  12. King FW, Ritner C, Liszewski W, Kwan HC, Pedersen A, Leavitt AD, Bernstein HS. Subpopulations of human embryonic stem cells with distinct tissue-specific fates can be selected from pluripotent cultures. Stem Cells Dev. 2009 Dec; 18(10):1441-50.
    View on PubMed
  13. Alian A, Griner SL, Chiang V, Tsiang M, Jones G, Birkus G, Geleziunas R, Leavitt AD, Stroud RM. Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs. Proc Natl Acad Sci U S A. 2009 May 19; 106(20):8192-7.
    View on PubMed
  14. Nicholas CR, Gaur M, Wang S, Pera RA, Leavitt AD. A method for single-cell sorting and expansion of genetically modified human embryonic stem cells. Stem Cells Dev. 2007 Feb; 16(1):109-17.
    View on PubMed
  15. Gaur M, Kamata T, Wang S, Moran B, Shattil SJ, Leavitt AD. Megakaryocytes derived from human embryonic stem cells: a genetically tractable system to study megakaryocytopoiesis and integrin function. J Thromb Haemost. 2006 Feb; 4(2):436-42.
    View on PubMed
  16. Watson SP, Bahou WF, Fitzgerald D, Ouwehand W, Rao AK, Leavitt AD. Mapping the platelet proteome: a report of the ISTH Platelet Physiology Subcommittee. J Thromb Haemost. 2005 Sep; 3(9):2098-101.
    View on PubMed
  17. Kamata T, Kang J, Lee TH, Wojnowski L, Pritchard CA, Leavitt AD. A critical function for B-Raf at multiple stages of myelopoiesis. Blood. 2005 Aug 1; 106(3):833-40.
    View on PubMed
  18. Kerrigan SW, Gaur M, Murphy RP, Shattil SJ, Leavitt AD. Caspase-12: a developmental link between G-protein-coupled receptors and integrin alphaIIbbeta3 activation. Blood. 2004 Sep 1; 104(5):1327-34.
    View on PubMed
  19. Gaur M, Murphy GJ, Frampton J, Leavitt AD. Using retroviruses to express genes in primary megakaryocyte lineage cells. Methods Mol Biol. 2004; 273:381-96.
    View on PubMed
  20. Kamata T, Pritchard CA, Leavitt AD. Raf-1 is not required for megakaryocytopoiesis or TPO-induced ERK phosphorylation. Blood. 2004 Apr 1; 103(7):2568-70.
    View on PubMed

Go to UCSF Profiles, powered by CTSI